Disclosures for "Pharmacokinetics of Staccato® Alprazolam in Healthy Adult Participants: Phase 1, Randomized, Placebo-controlled Ethno-bridging Study"
-
Dr. Roebling has received personal compensation for serving as an employee of UCB Biosciences GmbH. Dr. Roebling has stock in UCB Biosciences GmbH.
-
Mr. Hayakawa has nothing to disclose.
-
Miss Rospo has nothing to disclose.
-
Dr. Bartmann has nothing to disclose.
-
Aliceson King has received personal compensation for serving as an employee of UCB Pharma. Aliceson King has stock in UCB.
-
Hugues Chanteux, 18273 has nothing to disclose.